Two Bad Days in Biotech: A Cancer Drug Under Fire and a Weight-Loss Pill That Wasn't Enough
FDA review documents rattled Revolution Medicines investors by hinting its pancreatic cancer drug works better in some patients than others. Meanwhile, Zealand Pharma's obesity drug delivered solid results that would've been impressive five years ago, but in the age of GLP-1 blockbusters, "solid" doesn't cut it.
The FDA Quietly Dropped a Bomb
Imagine getting approved for a job, celebrating with champagne, and then finding out your new boss just told everyone you might not actually be qualified. That's roughly what happened to Revolution Medicines last week.
The company's pancreatic cancer drug Rasonque (daraxonrasib) won FDA approval back in August 2026. It was a big deal: a RAS-targeted therapy (meaning it goes after a specific cancer-driving protein called RAS) that beat chemotherapy in a Phase 3 trial on overall survival, progression-free survival, and tumor response rates. Revolution popped the champagne. Wall Street cheered.
Then on October 8, the FDA released review documents that told a more complicated story.
What the Documents Actually Said
Rasonque is approved for patients with metastatic pancreatic cancer who've already tried at least one other treatment. The drug targets tumors driven by KRAS mutations, which are like typos in the genetic code that tell cancer cells to grow nonstop. But not all KRAS typos are the same. There are subtypes: G12V, G12D, and G12R, among others.
The FDA's review documents broke down how well Rasonque worked in each of those subgroups. The results painted an uneven picture. Patients with G12V mutations appeared to benefit the most. Those with G12D mutations saw more modest results. And patients with G12R mutations fared the worst.
Now, a critical caveat: the FDA itself noted that these subgroup analyses were not designed for formal head-to-head comparisons. They were exploratory, like peeking at different slices of the data rather than running separate, rigorous experiments for each group. But investors don't always read the fine print. They saw "less effective in certain patients" and hit the sell button.
Analysts Say: Chill Out
The stock dropped to an intraday low near $180.52 before recovering to close around $189.76, which tells you some buyers stepped in once the panic subsided. And the analyst community was surprisingly unified in its response: this sell-off was overdone.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
RBC Capital Markets raised its price target to $259 and kept an Outperform rating. TD Cowen called the decline "overdone and misguided." Truist told clients the dip should be bought.
Their logic? The subgroup data was never meant to be the definitive word on which patients benefit most. The overall trial still showed a clear win across the full population. Revolution is also already running a new Phase 3 trial called RASolute 309, specifically testing a combination approach in first-line G12D pancreatic cancer, which could directly address the perceived weakness.
In other words, the company knew this question was coming and had already started working on the answer. Whether that's enough to convince skittish investors is another story.
Meanwhile, in Obesity Land: Zealand Brought a Knife to a Gunfight
Across the biotech landscape, a different kind of disappointment was unfolding. Zealand Pharma reported Phase 2 data for petrelintide, its once-weekly obesity and diabetes drug. The results were... fine. And in the obesity drug race, "fine" is a four-letter word.
Petrelintide produced up to 9.2% weight loss from baseline over 28 weeks in patients with obesity and type 2 diabetes. Placebo patients lost about 2%, giving the drug roughly a 7 percentage point advantage. The trial also showed meaningful reductions in HbA1c (a measure of blood sugar control), with placebo-adjusted improvements of 0.61% to 0.88%. And the tolerability was genuinely impressive: only 1.9% of patients on the drug dropped out due to GI side effects, compared to 1.7% on placebo. Essentially identical.
So why were analysts yawning?
The GLP-1 Problem
Because the obesity drug market has become the NBA of pharma, and the scoring averages keep going up. Semaglutide (Novo Nordisk's Wegovy) delivers roughly 15 to 17% weight loss. Eli Lilly's tirzepatide (Zepbound) pushes past 20%. And the next generation of triple-agonist drugs, like retatrutide, has posted a staggering 28.3% in Phase 3.
Against that backdrop, 9.2% over 28 weeks feels like bringing a solid B+ report card to a school where everyone else has straight A's. The drug works; it just doesn't dazzle.
Petrelintide takes a fundamentally different approach than GLP-1 drugs. It's an amylin analog, meaning it mimics a hormone that your pancreas naturally co-secretes with insulin. While GLP-1 drugs primarily suppress appetite (you just don't feel hungry), amylin works more through satiety: you feel full faster when you eat. Think of it as the difference between not wanting to go to the buffet versus going but stopping after one plate.
Where Zealand's Story Gets Interesting
The tolerability data is where petrelintide might carve out a real niche. GLP-1 drugs are famously harsh on the stomach. Nausea, vomiting, and diarrhea are so common that they've become punchlines. Zealand's drug, by contrast, showed GI side effects essentially indistinguishable from placebo. For patients who can't tolerate GLP-1s (and there are millions of them), that matters enormously.
There's also the combination angle. Zealand has designed petrelintide to be chemically stable and co-formulation friendly, meaning it could potentially be paired with GLP-1 drugs or other obesity medications to stack the weight-loss effects. In a market moving toward multi-drug cocktails, being a great dance partner might be more valuable than being a solo star.
But the market doesn't reward potential. It rewards proof. And right now, the proof says ~9% weight loss in a world that expects 15%+.
The Bigger Picture
These two stories look different on the surface: one's a cancer drug getting dinged by FDA documents, the other's an obesity drug that didn't wow. But they share the same underlying theme.
Biotech investors are ruthlessly comparative. Revolution's drug beat chemo across its full trial population, but the moment subgroup data looked uneven, the stock got hammered. Zealand's drug hit its primary endpoint with excellent tolerability, but because it wasn't as potent as GLP-1 leaders, the market shrugged.
The bar in biotech keeps rising. Beating placebo isn't enough. Beating the current standard of care isn't enough. You have to beat expectations, and expectations are shaped by whatever the best drug in the class has already proven.
For Revolution Medicines, the path forward is relatively clear: run the G12D-specific trial, prove the drug works there, and rebuild the narrative. For Zealand Pharma, the calculus is trickier. Petrelintide needs to find its lane, whether that's as a standalone option for GLP-1-intolerant patients or as a combination ingredient that boosts the ceiling for next-gen obesity treatment.
Both companies have real science and real clinical data. But in a market that grades on a curve, good isn't always good enough.
Deals & M&A5 min read
The AI Startup That Got Six Pharma Giants to Say Yes in Nine Months
An AI startup just convinced six of the world's biggest pharma companies to partner up in nine months flat. Chai Discovery's secret weapon? Its protein-folding models actually work when you test them in real labs, not just on screens.
